Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers
Scandinavian Journal of Gastroenterology , Volume 47 - Issue 2 p. 136- 147
Background and aims. Atrophic gastritis (AG) results most often from Helicobacter pylori (H. pylori) infection. AG is the most important single risk condition for gastric cancer that often leads to an acid-free or hypochlorhydric stomach. In the present paper, we suggest a rationale for noninvasive screening of AG with stomach-specific biomarkers. Methods. The paper summarizes a set of data on application of the biomarkers and describes how the test results could be interpreted in practice. Results. In AG of the gastric corpus and fundus, the plasma levels of pepsinogen I and/or the pepsinogen I/pepsinogen II ratio are always low. The fasting level of gastrin-17 is high in AG limited to the corpus and fundus, but low or non-elevated if the AG occurs in both antrum and corpus. A low fasting level of G-17 is a sign of antral AG or indicates high intragastric acidity. Differentiation between antral AG and high intragastric acidity can be done by assaying the plasma G-17 before and after protein stimulation, or before and after administration of the proton pump inhibitors (PPI). Amidated G-17 will rise if the antral mucosa is normal in structure. H. pylori antibodies are a reliable indicator of helicobacter infection, even in patients with AG and hypochlorhydria. Conclusions. Stomach-specific biomarkers provide information about the stomach health and about the function of stomach mucosa and are a noninvasive tool for diagnosis and screening of AG and acid-free stomach.
|Acetaldehyde, Achlorhydria, Atrophic gastritis, Biomarker, Calcium, Gastric cancer, Gastrin, Helicobacter pylori, Pepsinogen, Vitamin B12|
|Scandinavian Journal of Gastroenterology|
|Organisation||Department of Neurology|
Agreus, L, Kuipers, E.J, Kupcinskas, L, Malfertheiner, P, Di Mario, F, Leja, M, … Sung, J.J.Y. (2012). Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. Scandinavian Journal of Gastroenterology, 47(2), 136–147. doi:10.3109/00365521.2011.645501